ATE193323T1 - Verwendung einer zellulären zusammensetzung zur behandlung von menschlichen oder tierischen organismen - Google Patents

Verwendung einer zellulären zusammensetzung zur behandlung von menschlichen oder tierischen organismen

Info

Publication number
ATE193323T1
ATE193323T1 AT93900251T AT93900251T ATE193323T1 AT E193323 T1 ATE193323 T1 AT E193323T1 AT 93900251 T AT93900251 T AT 93900251T AT 93900251 T AT93900251 T AT 93900251T AT E193323 T1 ATE193323 T1 AT E193323T1
Authority
AT
Austria
Prior art keywords
treatment
human
animal organisms
compositions
cellular composition
Prior art date
Application number
AT93900251T
Other languages
English (en)
Inventor
Claude Roth
Lluis Mir
Philippe Kourilsky
Original Assignee
Pasteur Institut
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9418997&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE193323(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pasteur Institut, Inst Nat Sante Rech Med filed Critical Pasteur Institut
Application granted granted Critical
Publication of ATE193323T1 publication Critical patent/ATE193323T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT93900251T 1991-11-15 1992-11-13 Verwendung einer zellulären zusammensetzung zur behandlung von menschlichen oder tierischen organismen ATE193323T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9114119A FR2683725B1 (fr) 1991-11-15 1991-11-15 Composition cellulaire pour le traitement des organismes humains ou animaux.
PCT/FR1992/001061 WO1993010219A1 (fr) 1991-11-15 1992-11-13 Composition cellulaire pour le traitement des organismes humains ou animaux

Publications (1)

Publication Number Publication Date
ATE193323T1 true ATE193323T1 (de) 2000-06-15

Family

ID=9418997

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93900251T ATE193323T1 (de) 1991-11-15 1992-11-13 Verwendung einer zellulären zusammensetzung zur behandlung von menschlichen oder tierischen organismen

Country Status (13)

Country Link
US (1) US6074637A (de)
EP (1) EP0579791B1 (de)
JP (2) JPH06504450A (de)
AT (1) ATE193323T1 (de)
AU (1) AU671090B2 (de)
CA (1) CA2098720C (de)
DE (1) DE69231093T2 (de)
DK (1) DK0579791T3 (de)
ES (1) ES2146226T3 (de)
FR (1) FR2683725B1 (de)
GR (1) GR3034192T3 (de)
SG (1) SG48066A1 (de)
WO (1) WO1993010219A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5662896A (en) * 1988-03-21 1997-09-02 Chiron Viagene, Inc. Compositions and methods for cancer immunotherapy
DE4303751C1 (de) * 1993-02-09 1994-09-08 Intracon Sarl Verfahren zur Wiederverwertung von Filterstäuben
US20050169900A1 (en) * 1993-02-17 2005-08-04 Sloan Kettering Institute For Cancer Research Allogeneic vaccine and methods to synthesize same
DE69433110T2 (de) * 1993-02-17 2004-06-03 Sloan-Kettering Institute For Cancer Research Allogenes vakzin und synthesemethode für selbiges
FR2709309B1 (fr) * 1993-08-25 1995-11-10 Centre Nat Rech Scient Compositions cellulaires, préparation et utilisations thérapeutiques.
AUPM543894A0 (en) * 1994-05-04 1994-05-26 Commonwealth Scientific And Industrial Research Organisation An adjuvant
IL132164A0 (en) * 1997-04-09 2001-03-19 Chang Lung Ji Animal model for evaluation of vaccines
US6730512B2 (en) 1997-04-09 2004-05-04 Amdl, Inc. Combination immunogene therapy
ES2218994T3 (es) * 1998-02-02 2004-11-16 The Johns Hopkins University School Of Medicine Linea celular inmunomoduladora universal que expresa citocinas y composiciones relacionadas y procedimientos de fabricacion y uso.
US20030170898A1 (en) * 2001-12-04 2003-09-11 Gundersen Martin A. Method for intracellular modifications within living cells using pulsed electric fields
TWI776276B (zh) * 2019-11-13 2022-09-01 中國醫藥大學 異種組織細胞組合物治療癌症之用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783407A (en) * 1985-09-30 1988-11-08 Merck & Co., Inc. Growth of hepatitus A virus in vero cells
US5219740A (en) * 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
EP0456640A1 (de) * 1988-12-13 1991-11-21 UNITED STATES GOVERNMENT as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Genetisch erzeugte endothelzellen und deren verwendung
CA2091346C (en) * 1990-09-14 2007-04-24 Philip Frost Methods and compositions for genetic therapy and potentiation of anti-tumor immunity
US5358866A (en) * 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
DE69231250T2 (de) * 1991-10-21 2001-03-15 Cell Genesys, Inc. Kombinierte zelluläre und immunsuppressive therapien

Also Published As

Publication number Publication date
DE69231093T2 (de) 2001-02-01
JP2004026802A (ja) 2004-01-29
ES2146226T3 (es) 2000-08-01
WO1993010219A1 (fr) 1993-05-27
AU3163193A (en) 1993-06-15
FR2683725A1 (fr) 1993-05-21
DK0579791T3 (da) 2000-10-30
EP0579791B1 (de) 2000-05-24
AU671090B2 (en) 1996-08-15
JPH06504450A (ja) 1994-05-26
SG48066A1 (en) 1998-04-17
FR2683725B1 (fr) 1995-07-07
DE69231093D1 (de) 2000-06-29
EP0579791A1 (de) 1994-01-26
GR3034192T3 (en) 2000-11-30
CA2098720A1 (fr) 1993-05-16
US6074637A (en) 2000-06-13
CA2098720C (fr) 2003-01-21

Similar Documents

Publication Publication Date Title
DE69127175D1 (de) Antisens-Oligonukleotide zur Behandlung von Krebs
DE69231093D1 (de) Verwendung einer zellulären Zusammensetzung zur Behandlung von menschlichen oder tierischen Organismen
ATE450268T1 (de) G-csf zur behandlung von amyotropher lateralsklerose
FI844510A0 (fi) Ensym-resistenta immunsystemet modulerande peptider.
ATE230607T1 (de) Verwendung von neurturin protein zur vorbeugung und behandlung von gehörverlust
DE69733968D1 (de) Norbornen- und norbornandiolen zur behandlung von pigmentierungsstörungen, neurodegenerativen erkrankungen oder proliferativen hauterkrankungen
PT923293E (pt) Tratamento da diarreia
ATE332142T1 (de) Zusammensetzungen zur behandlung von tierischen krankheiten und syndromen mit transferfaktor
DE3482754D1 (de) Medikament und medikamentoese zusammensetzung zur behandlung und/oder verhinderung von hautkrankheiten, verursacht durch eine entzuendung.
SE8703696D0 (sv) Antioxidationsmedelskomposition och forfarande for framstellning derav
DE69328438D1 (de) Eichenrindenextraktverwandte synthetische zubereitungen und verfahren zur verwendung
ATE415962T1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
ES2034190T3 (es) Metodo de tratar fango de aguas residuales para proporcionar un fertilizante para terrenos agricolas.
ATE311853T1 (de) Verwendung von krillenzymen zur behandlung von zahnbelag
DE69902523D1 (de) Verwendung von erythropoietin zur behandlung von multiple myelom
DE69627354D1 (de) Verwendung von calendula-glykosiden zur behandlung der psoriasis
DK0574394T3 (da) I den humane terapi anvendelige stoffer af polypeptidnatur
ATE433461T1 (de) Rana pipiens proteine und deren verwendung in der behandlung von tumoren
SE8500470L (sv) Kompositioner for kosmetiskt, helso- och kroppsbevarande bruk
DE60015791D1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
ATE243522T1 (de) Verwendung von tall-104 zellen in kombination mit adriamyzin oder cisplatin zur behandlung von malignen tumoren
DE69933581D1 (de) Verwendung von humanem wachstumshormon zur vermehrung der anzahl zirkulierender cd34+ zellen, zur wiederherstellung des hämapoietischen- und des immunsystems nach myeloablativer oder antiblastischer therapie, bei transplantation oder re-infusion
DE69427188D1 (de) Zusammensetzung zur behandlung von tumoren und immunisierung von organismen gegen tumore
DE3485773D1 (de) Aus kultivierten mesenchymzellen extrahierte makromolekuele zur behandlung von degenerationskrankheiten.
Brown et al. Aquaculture as a Method for Meeting Hatchery Discharge Standards.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee